论文部分内容阅读
近年来,多项研究显示细胞周期蛋白依赖性激酶4和6(CDK4/6)抑制剂对于激素受体阳性晚期乳腺癌患者具有较好的疗效,甚至可改善内分泌耐药问题。相关研究表明CDK4/6抑制剂联合内分泌治疗在临床应用中极具前景。
In recent years, several studies have shown that inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 / 6) have a good effect on patients with hormone receptor-positive advanced breast cancer and may even improve the problem of endocrine resistance. Related studies have shown that CDK4 / 6 inhibitors combined with endocrine therapy in the clinical application of great prospects.